Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant factor » significant factors (Expand Search)
significant co » significant _ (Expand Search), significant gap (Expand Search), significant cause (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant factor » significant factors (Expand Search)
significant co » significant _ (Expand Search), significant gap (Expand Search), significant cause (Expand Search)
-
2321
Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i>
Published 2025“…The seroprevalence did not significantly decrease following DA treatment. These results include all individuals sampled, irrespective of whether they took the medications. …”
-
2322
NIE ELISA results.
Published 2025“…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
-
2323
Kato Katz and PCR database 12 months collection.
Published 2025“…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
-
2324
Master database baseline, 4 weeks and 1 year.
Published 2025“…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
-
2325
Percentage distribution of maternal deaths by cause of death, PDHS 2007 and PMMS 2019.
Published 2025Subjects: -
2326
Maternal mortality ratio (MMR) by cause of death, per 100,000 live births, PDHS 2007 and PMMS 2019.
Published 2025Subjects: -
2327
-
2328
-
2329
-
2330
MMR (maternal deaths per 100,000 live births) and 95% confidence limits, PDHS 2007 and PMMS 2019.
Published 2025Subjects: -
2331
-
2332
Recruitment flow diagram of the current study.
Published 2025“…Phase 1 EQ-VAS decreases were associated with female sex, lower somatic symptom, fewer comorbidities, lack of expectation for a fast recovery, higher ISS, higher injury pain, neck, spine/back or lower extremity injuries. …”
-
2333
Comparison of Analgesic Consumption by WHO Analgesic Level Between 2023 and 2022.
Published 2025Subjects: -
2334
-
2335
-
2336
-
2337
-
2338
-
2339
-
2340